January 2022

Presentations

SEA-CD40 | Pancreatic Ductal Adenocarcinoma | Abstract #559

Preliminary results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)

Tucatinib | Solid Tumors | Abstract #TPS489

SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: biliary tract cancer cohort (Trial in Progress)

Tucatinib | Gastrointestinal Cancers | Abstract #TPS376

Phase 1b/2, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (Trial in Progress)

Tucatinib | Gastrointestinal Carcinoma | Abstract #TPS371

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in Progress